Bispecific Antibody Targeted T Cell Therapy of Ovarian Cancer: Clinical Results and Future Directions-Reference-Cited by-同舟云学术

Bispecific Antibody Targeted T Cell Therapy of Ovarian Cancer: Clinical Results and Future Directions

Published:1995-10 Issue:5 Volume:4 Page:423-427
ISSN:1061-6128
Container-title:Journal of Hematotherapy
language:en
Short-container-title:Journal of Hematotherapy

Author:

CANEVARI SILVANA,MEZZANZANICA DELIA,MAZZONI ALESSANDRA,NEGRI DONATELLA R.M.,RAMAKRISHNA VENKATESH,BOLHUIS REINDER L.H.,COLNAGHI MARIA I.,BOLIS GIORGIO

Publisher

Mary Ann Liebert Inc

Subject

Hematology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/scd.1.1995.4.423

Reference26 articles.

1. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.

2. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

3. Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients

4. Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer

5. Ovarian carcinoma metastatic to the diaphragm—frequently undiagnosed at laparotomy

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecifics and antibody–drug conjugates: A positive synergy;Drug Discovery Today: Technologies;2018-12

2. Nature of tumour rejection antigens in ovarian cancer;Immunology;2018-06-13

3. T-cell target antigens across major gynecologic cancers;Gynecologic Oncology;2017-06

4. Surgical immune interventions for solid malignancies;The American Journal of Surgery;2016-10

5. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status;Journal of Controlled Release;2016-03